Search research articles
Contact Us
Filters
Showing results (1751-1760 of 1,779) with videos related to
Page
of 178
Sort By:
Mabs
|
May 27, 2023
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations
Indrajit Ghosh, Hiten Gutka, Mary E Krause, et al.
Mabs
|
February 22, 2026
Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Lood van Niekerk, Joshua Moller, Seth Ritter, et al.
Mabs
|
October 15, 2024
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
Cristina Melero, S Jimmy Budiardjo, Anahita Daruwalla, et al.
Mabs
|
October 14, 2024
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models
Yu Huang, Jinyong Wang, Xiling Wei, et al.
Mabs
|
May 13, 2026
Impact of process impurities on developability assessments of complex antibody formats: the striking role of leachable copper
Vincent Wieser, Christian Spick, Matthias Forster, et al.
Mabs
|
May 21, 2026
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates
Dirk van Lier, Magali Genest, Adrien Picod, et al.
Mabs
|
May 8, 2026
Machine learning predictions of IgG1 and IgG4 self-association and high-concentration solution properties
Na-Young Kwon, Chloe N Brown, Hsin-Ting Chen, et al.
Mabs
|
May 14, 2026
2D NMR assessment of structural consistency and functional relationships in monoclonal antibodies
Lingfei Wang, M Jasmin Donohue, Blaine Ballard, et al.
Mabs
|
March 18, 2026
AbDist: a lightweight, distance-based model for antibody affinity prediction as an interpretable benchmark for machine learning models
Marc Hoffstedt, Jannis Wowra, Hermann Wätzig, et al.
Mabs
|
June 10, 2026
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors
Welbeck Danquah, Mélanie Pichery, Thomas Eden, et al.
Page
of 178
Search research articles
Search
Showing results (1751-1760 of 1,779) with videos related to
Sort By:
Page
of 178
Mabs
|
May 27, 2023
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations
Indrajit Ghosh, Hiten Gutka, Mary E Krause, et al.
Mabs
|
February 22, 2026
Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
Lood van Niekerk, Joshua Moller, Seth Ritter, et al.
Mabs
|
October 15, 2024
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
Cristina Melero, S Jimmy Budiardjo, Anahita Daruwalla, et al.
Mabs
|
October 14, 2024
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models
Yu Huang, Jinyong Wang, Xiling Wei, et al.
Mabs
|
May 13, 2026
Impact of process impurities on developability assessments of complex antibody formats: the striking role of leachable copper
Vincent Wieser, Christian Spick, Matthias Forster, et al.
Mabs
|
May 21, 2026
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates
Dirk van Lier, Magali Genest, Adrien Picod, et al.
Mabs
|
May 8, 2026
Machine learning predictions of IgG1 and IgG4 self-association and high-concentration solution properties
Na-Young Kwon, Chloe N Brown, Hsin-Ting Chen, et al.
Mabs
|
May 14, 2026
2D NMR assessment of structural consistency and functional relationships in monoclonal antibodies
Lingfei Wang, M Jasmin Donohue, Blaine Ballard, et al.
Mabs
|
March 18, 2026
AbDist: a lightweight, distance-based model for antibody affinity prediction as an interpretable benchmark for machine learning models
Marc Hoffstedt, Jannis Wowra, Hermann Wätzig, et al.
Mabs
|
June 10, 2026
Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors
Welbeck Danquah, Mélanie Pichery, Thomas Eden, et al.
Page
of 178